by American Association for Cancer Research Credit: CC0 Public Domain First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results recently published in Clinical Cancer Research. Patients with high-risk CLL, defined by...
by Melissa Rohman, Northwestern University A Wright’s stained bone marrow aspirate smear of a patient with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk/Wikimedia/CC BY-SA 3.0 A combination therapy pairing a small molecule inhibitor with monoclonal antibody immunotherapy improved patient outcomes for relapsed chronic lymphocytic leukemia (CLL), according to a Northwestern Medicine clinical trial published in Blood. The...
